

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 13499

August 15, 1975, will be reviewed by the presiding officer prior to the hearing, so that full repetition at the hearing will be unnecessary. A participant may be accompanied by any number of additional persons.

If a participant is not present when his or her presentation is scheduled to begin, the participants following will be taken in order. An attempt will be made to hear any scheduled participant who misses his assigned time at the conclusion of the hearing. Other interested persons attending the hearing who did not request an opportunity to speak will be given an opportunity to make oral presentations at the conclusion of the hearing to the extent that time permits.

The presiding officer, as well as any other Food and Drug Administration employee serving with him as a panel, may question any participant during or at the conclusion of his presentation. No other persons attending the hearing may question a participant. The presiding officer may allot additional time to any participant if he concludes that it is in the public interest, but may not reduce the time allotted to anyone.

The record of the hearing will remain open until September 5, 1975, for the submission of any additional written statements or comments regarding oral presentations made at the hearing.

No written submission, or any portion thereof, made in response to this notice shall be received or held in confidence. The administrative record of this rule making proceeding shall consist of all relevant FEDERAL REGISTER notices and the documents to which they refer, all